Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

Heidi D. FinnesDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA;

Kari G. ChaffeeDepartment of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA;

Timothy G. CallDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Wei DingDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Saad S. KenderianDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Deborah A. BowenDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Michael ConteDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Kristen B. McCulloughDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA;

Julianna A. MertenDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA;

Gabriel T. BartooDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA;

Matthew D. SmithDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA;

Jose LeisDivision of Hematology Oncology, Mayo Clinic, Phoenix, AZ, USA;

Asher Chanan-KhanDivision of Hematology Oncology, Mayo Clinic, Jacksonville, FL, USA;

Susan M. SchwagerDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Susan L. SlagerDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

Neil E. KayDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Tait D. ShanafeltDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Sameer A. ParikhDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Correspondence[email protected]

Your download is now in progress and you may close this window